Management

Michael Brobjer

Michael Brobjer

CEO since 2018

Michael is a business oriented and flexible leader with extensive experience from the Life science and pharmaceutical industry. Michael has been working at KabiGen, Pharmacia and Pharmacia & UpJohn performing development of pharmaceuticals at different management levels. Michael has also been working in Business Development plus sales and marketing at Biovitrum (today Sobi) and as Marketing Director at APL (Apotek Produktion & Laboratorier). Prior to joining AroCell, Michael was CEO of Karessa Pharma, a Clinical stage pharma development company in Sweden. Has a M Sc.

Holdings in AroCell: 151 363 shares.
Warrants in AroCell: 400 000.

 

Anders Hultman

Anders Hultman

CFO since 2018

Anders Hultman started his employment at Arocell 2018. He has more than 15 years’ experience in managerial and executive positions within finance, sales, and marketing. Furthermore, he has extensive international experience from several executive positions such as CFO, Sales Director, Product Marketing Director, and CEO in pharma, IT, telecom, and e-commerce companies. He has also worked as a journalist at Reuters and founded several companies. Anders has a Bachelor of Science in Business Administration and Economics from Uppsala University.

Holdings in AroCell: 120 000 shares.
Warrants in AroCell: 300 000.

Cecilia Ahlin

Cecilia Ahlin

CMO since 2020

Cecilia Ahlin has over 20 years of experience in treating cancer patients and is still clinically active. Cecilia has a PhD in prognostic factors in breast cancer. She became a specialist in general oncology in 2003 and in gynecological oncology in 2011. She has experience from the Swedish MPA as a clinical assessor and most recently from Novartis where she was Medical Head Oncology Sweden. Cecilia holds an associate professorship in Oncology at Örebro University.

Holdings in AroCell: nil shares.

Staffan Eriksson

Staffan Eriksson

CSO since 2003

Staffan Eriksson has more than 35 years’ experience in medical biochemistry and cell biology with a PhD and an MD from the Karolinska Institute. He was appointed Professor in Medical and Physiological Chemistry at The Swedish University of Agricultural Sciences, Uppsala, in 1992. He has published more than 200 publications in peer-reviewed journals and supervised 15 doctoral students. Staffan is a leading scientist in the area of structure and function of Thymidine Kinase 1 with more than 100 publications during the last 10 years.

Staffan is one of the founders of AroCell and has served as CSO and Board Member of AroCell since 2003.

Holdings in AroCell: 422 450 shares.
Warrants in AroCell: 100 000.

PETER LÖWENDAHL

PETER LÖWENDAHL

Regulatory Affairs director since 2019

Peter Löwendahl has 30 years of experience working in regulatory affairs. He was previously responsible for quality and regulatory affairs at Elekta AB and globally responsible for regulatory affairs within GE Healthcare’s life science department. Peter Löwendahl has been working as a senior consultant and advisor for Hoff & Lowendahl AB since 2016.

 

KIRAN KUMAR JAGARLAMUDI

KIRAN KUMAR JAGARLAMUDI

Research Director since 2015

Kiran Kumar Jagarlamudi, PhD, is Clinical Research Manager at AroCell. He received his Bachelor’s Degree in Veterinary Sciences from the College of Veterinary Sciences, Hyderabad, India. He became Masters in Animal Science at the Swedish Agricultural University in Uppsala Sweden and obtained the degree of PhD in Veterinary Medicine (Biochemistry) in 2015 at the same institution. Since 2010, he has been working with different biochemical aspects of cellular and serum forms of thymidine kinase 1 (TK1) from both humans as well as dogs. He was also involved in the evaluation of early versions of AroCell TK 210 ELISA kits and characterization of TK1 antibodies.

Holdings in AroCell: 10000 shares.
Warrants in AroCell: 100 000.

Alona Nyberg

Alona Nyberg

Marketing Director since 2019

Alona has studied the Master of Science in Molecular Biotechnology at Uppsala University, and Entrepreneurship at the School of Entrepreneurship. She has worked as a consultant at Uppstuk and Thermo Fischer Scientific before joining AroCell AB in 2017 as a Marketing and Sales Assistant.

Holdings in AroCell: 666 shares.
Warrants in AroCell: 100 000.

Martin Shaw

Martin Shaw

Senior Director of Business Development since 2016

Martin Shaw joined AroCell as Business Development Manager in 2016. He has over 40 years’ experience in the development and introduction of novel biomarker assays to the pharmaceutical, biotechnology and laboratory medicine industries. Martin started his career at Pharmacia Diagnostics (now Thermo-Fisher) where he held many technical, sales and marketing positions, He also worked at EKF Diagnostics where he introduced and promoted a wide range of toxicology and organ damage biomarker assays. He developed strong relationships with clinical research organisations and pharmaceutical companies and participated in cross-industry working parties on biomarker validation and registration. Martin has a BSc.

Holdings in AroCell: nil shares.

FILIP FOGDESTAM

FILIP FOGDESTAM

Logistics Director since 2014

Filip Fogdestam is Head of Operations at AroCell since 2014. He runs a consultancy business, working with various life science start-ups since 2012. His experience includes Marketing Director and General Manager at MAIIA Diagnostics AB, and he has worked for MIAB AB and Phadia AB. He has also worked in the telecom sector. Filip has studied business administration at Uppsala University and the Swedish University of Agriculture and entrepreneurship and business acceleration in London, UK.

Holdings in AroCell: 279 928 shares.

ALF MALMBERG

ALF MALMBERG

Quality Assurance Director since 2014

Alf Malmberg (PhD) Manager QA&RA at AroCell has been working in the medical device business for 30 years. Mainly in Carmeda AB starting with product development and since 1987 QA&RA Manager. Since 2004 Alf Malmberg is Senior QA & RA Consultant, designing and implementing quality systems and technical files for small and medium sized companies.

Holdings in AroCell: 15 199 shares.